{"id":40562,"date":"2025-06-13T14:06:27","date_gmt":"2025-06-13T12:06:27","guid":{"rendered":"https:\/\/www.idisantiago.es\/?post_type=project&#038;p=40562"},"modified":"2026-04-15T13:16:56","modified_gmt":"2026-04-15T11:16:56","slug":"ga01-lugo-1","status":"publish","type":"project","link":"https:\/\/www.idisantiago.es\/gl\/grupo-de-investigacion\/ga01-lugo-1\/","title":{"rendered":"Grupo de Investigaci\u00f3n Oncolog\u00eda Traslacional- Hospital Universitario Lucus Augusti (GIOT-HULA)"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;0px||||false|false&#8221; da_disable_devices=&#8221;off|off|off&#8221; global_colors_info=&#8221;{}&#8221; da_is_popup=&#8221;off&#8221; da_exit_intent=&#8221;off&#8221; da_has_close=&#8221;on&#8221; da_alt_close=&#8221;off&#8221; da_dark_close=&#8221;off&#8221; da_not_modal=&#8221;on&#8221; da_is_singular=&#8221;off&#8221; da_with_loader=&#8221;off&#8221; da_has_shadow=&#8221;on&#8221;][et_pb_row _builder_version=&#8221;4.21.0&#8243; _module_preset=&#8221;default&#8221; width=&#8221;100%&#8221; custom_padding=&#8221;0px||||false|false&#8221; locked=&#8221;off&#8221; collapsed=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.21.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>&nbsp;<\/p>\n<p><a href=\"https:\/\/www.idisantiago.es\/gl\/grupos-de-investigacion\/\"><strong>GRUPOS DE INVESTIGACI\u00d3N<\/strong><\/a><\/p>\n<h1>Grupo de Investigaci\u00f3n Oncolog\u00eda Traslacional- Hospital Universitario Lucus Augusti (GIOT-HULA)<\/h1>\n<p>&nbsp;<\/p>\n<p>CATEGOR\u00cdA: <span style=\"color: #003366;\">GRUPOS COLABORADORES<\/span><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;2_3,1_3&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; width=&#8221;100%&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;2_3&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image title_text=&#8221;IMG-20230418-WA0000&#8243; disabled_on=&#8221;on|on|on&#8221; _builder_version=&#8221;4.21.0&#8243; _module_preset=&#8221;default&#8221; disabled=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_toggle title=&#8221;Objetivos y l\u00edneas de investigaci\u00f3n&#8221; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Objetivos y l\u00edneas de investigaci\u00f3n&#8221; _builder_version=&#8221;4.21.0&#8243; _module_preset=&#8221;default&#8221; body_font=&#8221;|300|||||||&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3>Objetivos<\/h3>\n<p>Nuestro grupo de investigaci\u00f3n se centra en el trabajo colaborativo entre el cl\u00ednico y el investigador de cara a tener un mayor conocimiento del c\u00e1ncer que permita establecer en el futuro tratamientos m\u00e1s efectivos y personalizados.<\/p>\n<h3>L\u00edneas de investigaci\u00f3n<\/h3>\n<p>\u2022 Investigaci\u00f3n de las bases moleculares de distintos tipos de c\u00e1ncer, principalmente los de vejiga, pulm\u00f3n y mama.<br \/>\u2022 Desarrollo de nuevas t\u00e9cnicas de diagn\u00f3stico del c\u00e1ncer mediante t\u00e9cnicas no invasivas (empleo de muestras de suero\/plasma sangu\u00edneo y orina).<br \/>\u2022 Estudio del papel que el microbioma intestinal tiene como biomarcador de desarrollo y pron\u00f3stico en el desarrollo del c\u00e1ncer de mama.<br \/>\u2022 Procurar marcadores cl\u00ednicos, radiol\u00f3gicos, celulares y moleculares que definan los patrones de respuesta a los tratamientos empleados en la pr\u00e1ctica cl\u00ednica.<br \/>\u2022 Uso de t\u00e9cnicas prote\u00f3micas y gen\u00f3micas para el descubrimiento, en enfermedades tumorales, de marcadores tempranos de diagn\u00f3stico y de predicci\u00f3n del progreso y de la respuesta a tratamiento.<\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_toggle][et_pb_toggle title=&#8221;Equipo investigador&#8221; admin_label=&#8221;Equipo investigador&#8221; _builder_version=&#8221;4.21.0&#8243; _module_preset=&#8221;default&#8221; body_font=&#8221;|300|||||||&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<table style=\"width: 100%; border-collapse: collapse; border-style: hidden;\" border=\"0\">\n<tbody>\n<tr>\n<td style=\"width: 50%;\"><strong>L\u00edder<\/strong><br \/>V\u00e1zquez Est\u00e9vez, Sergio<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Miembros<\/strong><br \/>\u00c1lvarez G\u00f3mez, Elena<br \/>Campos Balea, Bego\u00f1a<br \/>Carnero L\u00f3pez, Beatriz<br \/>Casas Nebra, Francisco Javier<br \/>Covela R\u00faa, Marta<br \/>de Alba Acevedo, Luz<br \/>Fern\u00e1ndez N\u00fa\u00f1ez, Natalia<br \/>Ferreira Freire, Laura<br \/>Fern\u00e1ndez Sobrado, Ignacio<br \/>Gonz\u00e1lez G\u00f3mez, Borja<br \/>Mateos Mart\u00edn, Jes\u00fas<br \/>P\u00e9rez Fojo, Morgana<br \/>Quintero Aldana, Guillermo<br \/>T\u00e1vara Silva, Blanca<br \/>Varela Ferreiro, Silvia<\/p>\n<\/td>\n<td style=\"width: 50%;\">\u00a0<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>[\/et_pb_toggle][et_pb_toggle title=&#8221;Proyectos&#8221; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Proyectos (cambiar s\u00f3 codigo IDIS)&#8221; _builder_version=&#8221;4.21.0&#8243; _module_preset=&#8221;default&#8221; body_font=&#8221;|300|||||||&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Determinaci\u00f3n de la concentraci\u00f3n de inmunomarcadores (citoquinas, quimioquinas y factores de crecimiento) presentes en cada una de las muestras (sangre y orina) empleando los kits Bio-Plex Pro\u2122 Human Chemokine IFN-\u03b3 Set y Bio-Plex Pro\u2122 Human Cytokine 8-plex Assay (Bio-Rad) del ensayo cl\u00ednico \u201cEfficacy of Atezolizumab concurrent with radiotherapy in patients with muscle-invasive bladder cancer (ATEZOBLADDERPRESERVE)\u201d \u201d<br \/>Entidad financiadora: Grupo Espa\u00f1ol de Oncolog\u00eda Genitourinaria (SOGUG) (promotor) con la colaboraci\u00f3n de Roche. (C\u00f3digo: SOGUG-2017-A-IEC (VEJ)-4)<br \/>Financiaci\u00f3n obtenida: 92.284,50 Euros<br \/>Duraci\u00f3n: 2020-2027<\/p>\n<p>Estudio del microbioma Intestinal en pacientes de c\u00e1ncer de mama luminal<br \/>Entidad financiadora: Fundaci\u00f3n Sociedad Oncolog\u00eda de Galicia (FSOG) Oncolog\u00eda de Precisi\u00f3n<br \/>Financiaci\u00f3n obtenida: 20.000,00 Euros<br \/>Duraci\u00f3n: 2024-2026<br \/>Investigador principal: Ignacio Fern\u00e1ndez Sobrado<\/p>\n<p>[\/et_pb_toggle][et_pb_toggle title=&#8221;Publicaciones&#8221; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Publicaciones&#8221; _builder_version=&#8221;4.21.0&#8243; _module_preset=&#8221;default&#8221; body_font=&#8221;|300|||||||&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Fern\u00e1ndez Calvo O, Mu\u00f1oz Iglesias J, Abou Jokh Casas E, Molina-D\u00edaz A, Anido Herranz U, Casas Nebra J, Garc\u00eda-Bernardo L, Mart\u00ednez-Breijo S, L\u00e1zaro-Quintela M, Mu\u00f1iz-Garc\u00eda G, V\u00e1zquez-Estevez S. Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of\u00a0177Lu-PSMA-617 radioligand-therapy in prostate cancer. Clin Transl Oncol. 2024 Sep 12. doi: 10.1007\/s12094-024-03662-7. DOI:\u00a010.1007\/s12094-024-03662-7<\/p>\n<p>Provencio M, Robado de Lope L, Serna-Blasco R, Nadal E, Diz Tain P, Massuti B, Gonz\u00e1lez-Larriba JL, Insa A, S\u00e1nchez-Hern\u00e1ndez A, Casal-Rubio J, Garc\u00eda-Campelo R, Sequero L\u00f3pez S, Rogado J, Mart\u00ednez-Mart\u00ed A, Bosch-Barrera J, Bernab\u00e9 R, V\u00e1zquez Est\u00e9vez S, Ponce S, de Castro J, Coves Sarto J, Reguart N, D\u00f3mine M, Aguilar A, Majem M, Estival A, Pe\u00f1a Cabia S, L\u00f3pez Mart\u00edn A, Sala Gonz\u00e1lez M\u00c1, Cobo M, Camps C, Barneto I, Calvo V, Collazo-Lorduy A, Cruz-Berm\u00fadez A, Romero A. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC. Lung Cancer. 2024 Aug;194:107865. DOI:10.1016\/j.lungcan.2024.107865<\/p>\n<p>Motzer RJ, Russo P, Gr\u00fcnwald V, Tomita Y, Zurawski B, Parikh O, Buti S, Barth\u00e9l\u00e9my P, Goh JC, Ye D, Lingua A, Lattouf JB, Albig\u00e8s L, George S, Shuch B, Sosman J, Staehler M, V\u00e1zquez Est\u00e9vez S, Simsek B, Spiridigliozzi J, Chudnovsky A, Bex A. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. Lancet. 2023 Mar 11;401(10379):821-832. DOI:\u00a010.1016\/S0140-6736(22)02574-0<\/p>\n<p>Fernandez-Perez MP, Perez-Navarro E, Alonso-Gordoa T, Conteduca V, Font A, V\u00e1zquez-Est\u00e9vez S, Gonz\u00e1lez-Del-Alba A, Wetterskog D, Antonarakis ES, Mellado B, Fernandez-Calvo O, M\u00e9ndez-Vidal MJ, Climent MA, Duran I, Gallardo E, Rodriguez Sanchez A, Santander C, S\u00e1ez MI, Puente J, Tudela J, Mart\u00ednez A, L\u00f3pez-Andreo MJ, Padilla J, Lozano R, Hervas D, Luo J, de Giorgi U, Castellano D, Attard G, Grande E, Gonzalez-Billalabeitia E. A correlative biomarker study and integrative prognostic model in chemotherapy-na\u00efve metastatic castration-resistant prostate cancer treated with enzalutamide. Prostate. 2023 Mar;83(4):376-384. DOI:\u00a010.1002\/pros.24469<\/p>\n<p>Bellmunt J, Valderrama BP, Puente J, Grande E, Bol\u00f3s MV, Lainez N, V\u00e1zquez S, Maroto P, Climent M\u00c1, Garcia Del Muro X, Arranz J\u00c1, Dur\u00e1n I. Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management. Crit Rev Oncol Hematol. 2022 Jun;174:103683. DOI:\u00a010.1016\/j.critrevonc.2022.103683<\/p>\n<p>Provencio M, Rodr\u00edguez-Abreu D, Ortega AL, Serrano G, Aguado C, Franco F, Gutierrez V, L\u00f3pez Vivanco G, Guirado M, Ben\u00edtez G, Estival A, Calvo V, Jim\u00e9nez B, Arasanz H, Coves J, Majem M, Massut\u00ed B, V\u00e1zquez S, Juan-Vidal O, Collazo-Lorduy A, Goz\u00e1lvez CL, Del Barco E, Rosero A, Bosch-Barrerra J, Moreno MA, Mielgo-Rubio X, Villa JC, L\u00f3pez-Martin A, C\u00f3rdoba JF, de As\u00eds Aparisi F, Zafra M, Mosquera J, P\u00e9rez Altozano J, Nadal E, Catot S, Balsalobre J, de Portugal T, Mart\u00edn P, Cuesta de Juan S, Cobo M. Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study. Transl Lung Cancer Res. 2022 Jan;11(1):53-63. DOI:\u00a010.21037\/tlcr-21-504<\/p>\n<p>[\/et_pb_toggle][et_pb_toggle title=&#8221;Web del grupo&#8221; disabled_on=&#8221;on|on|on&#8221; admin_label=&#8221;Web del grupo&#8221; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; body_font=&#8221;|300|||||||&#8221; disabled=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>https:\/\/<\/p>\n<p>[\/et_pb_toggle][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text admin_label=&#8221;Investigador\/a l\u00edder&#8221; _builder_version=&#8221;4.21.0&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#FFFFFF&#8221; header_text_color=&#8221;#FFFFFF&#8221; header_2_text_align=&#8221;left&#8221; header_2_text_color=&#8221;#FFFFFF&#8221; background_color=&#8221;#10294c&#8221; custom_margin=&#8221;0px||||false|false&#8221; custom_padding=&#8221;6px||0px|6px|false|false&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2>Investigadora l\u00edder<\/h2>\n<p>[\/et_pb_text][et_pb_text admin_label=&#8221;WP Team (cambiar s\u00f3 a ID pola do l\u00edder de equipo)&#8221; _builder_version=&#8221;4.21.0&#8243; _module_preset=&#8221;default&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<div class=\"sp-wp-team-pro-wrapper wp-team-pro-preloader\" >\n\n<div id=\"sptp-40527\" class=\"sp-team-pro sptp-section sptp-modal pagination_number sptp-even\" >\n\n\t<div class=\"sp-team-pro-page-loading-image\"><\/div>\n\t<div class=\"sptp-grid\">\n\t\t<div class=\"sptp-row  \">\n\t\t\t\t\t<div class=\"sp-team-pro-item sptp-col-lg-1 sptp-col-md-1 sptp-col-sm-1 sptp-col-xs-1\"\n\t\t\t data-member=\"40603\">\n\t\t\t\t<div class=\"sptp-member  border-bg-around-member sptp-square\">\n\t<a class=\"sptp-member-avatar  sptp-popup-trigger \"  href=javascript:void(0) target=_blank >\n\t<div class=\"sptp-member-avatar-img-area\" data-id=\"40603\">\n\t\t<div class=\"sptp-member-avatar-img sptp-square sptp-icon-on-image none \">\n\t\t\t<div class=\"sptp-overflow-h\">\n\t\t\t\t\t\t\t\t\t<div class=\"sptp-icon text-center\">\n\t\t\t\t\t<i class=\"fa fa-plus\"><\/i>\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" class=\"sptp_default_img\" srcset=\"https:\/\/www.idisantiago.es\/wp-content\/uploads\/2025\/06\/Sergio-Vazquez-modificada-IDIS.jpg\" src=\"https:\/\/www.idisantiago.es\/wp-content\/uploads\/2025\/06\/Sergio-Vazquez-modificada-IDIS.jpg\" alt=\"Sergio V\u00e1zquez Est\u00e9vez\" width=\"478\" height=\"359\">\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/a>\n\t<div class=\"sptp-member-name \">\n\t\t<h2>\n\t\t\t\t\tSergio V\u00e1zquez Est\u00e9vez\t\t\t\t<\/h2>\n\t<\/div>\n<div class=\"sptp-member-profession\">\n\t\t\t<h4>Investigador l\u00edder del Grupo de Investigaci\u00f3n Oncolog\u00eda Traslacional- Hospital Universitario Lucus Augusti (GIOT-HULA)<\/h4>\n\t<\/div>\n<div class=\"sptp-member-email\">\n\n<i class=\"fa fa-envelope\"><\/i>\t<a href=\"#0\"  class=\"\">\n\t\t<span>Sergio.Vazquez.Estevez@sergas.es<\/span>\n\t<\/a>\n\t<\/div>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div> <!-- end row -->\n\t<\/div> <!-- end grid -->\n\t\t\t<\/div>\n<\/div>\n\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; GRUPOS DE INVESTIGACI\u00d3N Grupo de Investigaci\u00f3n Oncolog\u00eda Traslacional- Hospital Universitario Lucus Augusti (GIOT-HULA) &nbsp; CATEGOR\u00cdA: GRUPOS COLABORADORESObjetivos Nuestro grupo de investigaci\u00f3n se centra en el trabajo colaborativo entre el [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":40596,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"footnotes":""},"project_category":[891],"project_tag":[],"class_list":["post-40562","project","type-project","status-publish","has-post-thumbnail","hentry","project_category-grupos-colaboradores-gl"],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/www.idisantiago.es\/gl\/wp-json\/wp\/v2\/project\/40562","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.idisantiago.es\/gl\/wp-json\/wp\/v2\/project"}],"about":[{"href":"https:\/\/www.idisantiago.es\/gl\/wp-json\/wp\/v2\/types\/project"}],"author":[{"embeddable":true,"href":"https:\/\/www.idisantiago.es\/gl\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.idisantiago.es\/gl\/wp-json\/wp\/v2\/comments?post=40562"}],"version-history":[{"count":9,"href":"https:\/\/www.idisantiago.es\/gl\/wp-json\/wp\/v2\/project\/40562\/revisions"}],"predecessor-version":[{"id":46448,"href":"https:\/\/www.idisantiago.es\/gl\/wp-json\/wp\/v2\/project\/40562\/revisions\/46448"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.idisantiago.es\/gl\/wp-json\/wp\/v2\/media\/40596"}],"wp:attachment":[{"href":"https:\/\/www.idisantiago.es\/gl\/wp-json\/wp\/v2\/media?parent=40562"}],"wp:term":[{"taxonomy":"project_category","embeddable":true,"href":"https:\/\/www.idisantiago.es\/gl\/wp-json\/wp\/v2\/project_category?post=40562"},{"taxonomy":"project_tag","embeddable":true,"href":"https:\/\/www.idisantiago.es\/gl\/wp-json\/wp\/v2\/project_tag?post=40562"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}